Proceeding of the European Group for Blood and Marrow Transplantation (EBMT) congress on sickle cell disease, 16–17 may 2019, Regensburg, Germany
Antithymocyte globulin (ATG) is a widely accepted part of the conditioning regimen applied in the setting of hematopoietic stem cell transplantation (HSCT) to prevent graft rejection and graft-versus-host disease. Although weight-based dosing of ATG has been introduced to optimize ATG dosing, substa...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-06-01
|
| Series: | Hematology/Oncology and Stem Cell Therapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1658387620300182 |
| id |
doaj-972a034d1f644e6eaabffb4845fc5903 |
|---|---|
| record_format |
Article |
| spelling |
doaj-972a034d1f644e6eaabffb4845fc59032020-11-25T03:33:49ZengElsevierHematology/Oncology and Stem Cell Therapy1658-38762020-06-011326165Proceeding of the European Group for Blood and Marrow Transplantation (EBMT) congress on sickle cell disease, 16–17 may 2019, Regensburg, GermanyLisa V.E. Oostenbrink0Cornelia M. Jol-van der Zijde1Anja M. Jansen-Hoogendijk2Emma S. Pool3Astrid G.S. van Halteren4Dirk Jan A.R. Moes5Robbert G.M. Bredius6Alex B. Mohseny7Frans J.W. Smiers8Maarten J.D. van Tol9Marco W. Schilham10Arjan C. Lankester11Corresponding author at: Department of Pediatrics, Leiden University Medical Center, P3-024, P.O. Box 9600, 2300 RC Leiden, The Netherlands.; Department of Pediatrics, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Pediatrics, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Pediatrics, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Pediatrics, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Pediatrics, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Pediatrics, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Pediatrics, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Pediatrics, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Pediatrics, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Pediatrics, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Pediatrics, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Pediatrics, Leiden University Medical Center, Leiden, the NetherlandsAntithymocyte globulin (ATG) is a widely accepted part of the conditioning regimen applied in the setting of hematopoietic stem cell transplantation (HSCT) to prevent graft rejection and graft-versus-host disease. Although weight-based dosing of ATG has been introduced to optimize ATG dosing, substantial variance in clearance of active ATG, the actual lymphocyte binding component, remains a challenge. Therefore, further research regarding ATG pharmacokinetics and pharmacodynamics in different HSCT settings and in patients with different types of underlying diseases is required.http://www.sciencedirect.com/science/article/pii/S1658387620300182ATGGrafalonThymoglobulinHaploidentical HSCTPediatricsSickle cell disease |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Lisa V.E. Oostenbrink Cornelia M. Jol-van der Zijde Anja M. Jansen-Hoogendijk Emma S. Pool Astrid G.S. van Halteren Dirk Jan A.R. Moes Robbert G.M. Bredius Alex B. Mohseny Frans J.W. Smiers Maarten J.D. van Tol Marco W. Schilham Arjan C. Lankester |
| spellingShingle |
Lisa V.E. Oostenbrink Cornelia M. Jol-van der Zijde Anja M. Jansen-Hoogendijk Emma S. Pool Astrid G.S. van Halteren Dirk Jan A.R. Moes Robbert G.M. Bredius Alex B. Mohseny Frans J.W. Smiers Maarten J.D. van Tol Marco W. Schilham Arjan C. Lankester Proceeding of the European Group for Blood and Marrow Transplantation (EBMT) congress on sickle cell disease, 16–17 may 2019, Regensburg, Germany Hematology/Oncology and Stem Cell Therapy ATG Grafalon Thymoglobulin Haploidentical HSCT Pediatrics Sickle cell disease |
| author_facet |
Lisa V.E. Oostenbrink Cornelia M. Jol-van der Zijde Anja M. Jansen-Hoogendijk Emma S. Pool Astrid G.S. van Halteren Dirk Jan A.R. Moes Robbert G.M. Bredius Alex B. Mohseny Frans J.W. Smiers Maarten J.D. van Tol Marco W. Schilham Arjan C. Lankester |
| author_sort |
Lisa V.E. Oostenbrink |
| title |
Proceeding of the European Group for Blood and Marrow Transplantation (EBMT) congress on sickle cell disease, 16–17 may 2019, Regensburg, Germany |
| title_short |
Proceeding of the European Group for Blood and Marrow Transplantation (EBMT) congress on sickle cell disease, 16–17 may 2019, Regensburg, Germany |
| title_full |
Proceeding of the European Group for Blood and Marrow Transplantation (EBMT) congress on sickle cell disease, 16–17 may 2019, Regensburg, Germany |
| title_fullStr |
Proceeding of the European Group for Blood and Marrow Transplantation (EBMT) congress on sickle cell disease, 16–17 may 2019, Regensburg, Germany |
| title_full_unstemmed |
Proceeding of the European Group for Blood and Marrow Transplantation (EBMT) congress on sickle cell disease, 16–17 may 2019, Regensburg, Germany |
| title_sort |
proceeding of the european group for blood and marrow transplantation (ebmt) congress on sickle cell disease, 16–17 may 2019, regensburg, germany |
| publisher |
Elsevier |
| series |
Hematology/Oncology and Stem Cell Therapy |
| issn |
1658-3876 |
| publishDate |
2020-06-01 |
| description |
Antithymocyte globulin (ATG) is a widely accepted part of the conditioning regimen applied in the setting of hematopoietic stem cell transplantation (HSCT) to prevent graft rejection and graft-versus-host disease. Although weight-based dosing of ATG has been introduced to optimize ATG dosing, substantial variance in clearance of active ATG, the actual lymphocyte binding component, remains a challenge. Therefore, further research regarding ATG pharmacokinetics and pharmacodynamics in different HSCT settings and in patients with different types of underlying diseases is required. |
| topic |
ATG Grafalon Thymoglobulin Haploidentical HSCT Pediatrics Sickle cell disease |
| url |
http://www.sciencedirect.com/science/article/pii/S1658387620300182 |
| work_keys_str_mv |
AT lisaveoostenbrink proceedingoftheeuropeangroupforbloodandmarrowtransplantationebmtcongressonsicklecelldisease1617may2019regensburggermany AT corneliamjolvanderzijde proceedingoftheeuropeangroupforbloodandmarrowtransplantationebmtcongressonsicklecelldisease1617may2019regensburggermany AT anjamjansenhoogendijk proceedingoftheeuropeangroupforbloodandmarrowtransplantationebmtcongressonsicklecelldisease1617may2019regensburggermany AT emmaspool proceedingoftheeuropeangroupforbloodandmarrowtransplantationebmtcongressonsicklecelldisease1617may2019regensburggermany AT astridgsvanhalteren proceedingoftheeuropeangroupforbloodandmarrowtransplantationebmtcongressonsicklecelldisease1617may2019regensburggermany AT dirkjanarmoes proceedingoftheeuropeangroupforbloodandmarrowtransplantationebmtcongressonsicklecelldisease1617may2019regensburggermany AT robbertgmbredius proceedingoftheeuropeangroupforbloodandmarrowtransplantationebmtcongressonsicklecelldisease1617may2019regensburggermany AT alexbmohseny proceedingoftheeuropeangroupforbloodandmarrowtransplantationebmtcongressonsicklecelldisease1617may2019regensburggermany AT fransjwsmiers proceedingoftheeuropeangroupforbloodandmarrowtransplantationebmtcongressonsicklecelldisease1617may2019regensburggermany AT maartenjdvantol proceedingoftheeuropeangroupforbloodandmarrowtransplantationebmtcongressonsicklecelldisease1617may2019regensburggermany AT marcowschilham proceedingoftheeuropeangroupforbloodandmarrowtransplantationebmtcongressonsicklecelldisease1617may2019regensburggermany AT arjanclankester proceedingoftheeuropeangroupforbloodandmarrowtransplantationebmtcongressonsicklecelldisease1617may2019regensburggermany |
| _version_ |
1724561437258416128 |